ER+ Breast Cancer Clinical Trials

26 clinical trials for ER+ Breast Cancer across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer — RECRUITING · PHASE1
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer — RECRUITING · PHASE1
• A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer — RECRUITING · PHASE2
• 4FMFES-PET Imaging of ER+ Advanced Breast Cancers — RECRUITING · PHASE2
• Circulating Tumor DNA — RECRUITING · PHASE2
• A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer — RECRUITING · PHASE2
• Breast Cancer Evolution During Neoadjuvant Systemic Therapy — RECRUITING
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
• JAB-2485 Activity in Adult Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC — RECRUITING · PHASE1
• Breast Re-irradiation After Second Ipsilateral Lumpectomy — RECRUITING · NA
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer — RECRUITING · PHASE2
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications — TERMINATED · PHASE1
• Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression — ACTIVE_NOT_RECRUITING · PHASE2
• Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. — ACTIVE_NOT_RECRUITING · PHASE1
• Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. — NOT_YET_RECRUITING
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. — ACTIVE_NOT_RECRUITING · PHASE1
• Alcohol and Breast Cancer (ABC) Trial — COMPLETED · NA
• Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) — OTHER · PHASE2
• Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer — NOT_YET_RECRUITING · PHASE3
• Tamoxifen Prediction Study in Patients With ER+ Breast Cancer — OTHER · PHASE4
• Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing — COMPLETED · PHASE2
• Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer — COMPLETED · PHASE2
• Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels — COMPLETED · NA
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) — COMPLETED · PHASE1
• Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients — COMPLETED · PHASE1

Refine this search